• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名患有中枢性甲状腺功能亢进症的巨大青少年患者的 Pit-1 谱系单形性多激素垂体腺瘤。

Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

作者信息

Pereira Bernardo Dias, Raimundo Luísa, Mete Ozgur, Oliveira Ana, Portugal Jorge, Asa Sylvia L

机构信息

Serviço de Endocrinologia e Diabetes, piso 8, Hospital Garcia de Orta, E.P.E, 2801-951, Almada-Setúbal, Portugal.

Department of Pathology, University Health Network, 200 Elizabeth Street, 11th Floor, Toronto, ON, Canada.

出版信息

Endocr Pathol. 2016 Mar;27(1):25-33. doi: 10.1007/s12022-015-9395-2.

DOI:10.1007/s12022-015-9395-2
PMID:26330191
Abstract

Thyrotropin (TSH)-secreting pituitary adenomas are exceedingly rare at the pediatric age and no cases of co-secretion with other pituitary hormones in these tumors have been described in this age range. We present a case of a monomorphous plurihormonal pituitary adenoma that co-secreted TSH and GH in a pediatric patient. A 13-year-old male presented with increasing height velocity (17.75 cm/year, 9.55SD), weight loss, and visual impairment. Initial biochemical evaluations revealed secondary hyperthyroidism. A giant pituitary tumor compressing the surrounding structures was detected by magnetic resonance, and a transsphenoidal surgery was initially performed. Pathological examinations revealed an atypical, monomorphous plurihormonal Pit-1 lineage tumor with mixed features of silent subtype 3 adenoma and acidophil stem cell adenoma. In the postoperative period, secondary hyperthyroidism recurred with high levels of both GH and IGF1. In addition, due to tumor re-growth, a multimodality treatment plan was undertaken including surgery, somatostatin analogs, and radiotherapy. We report the first pediatric case of a plurihormonal TSH- and GH-secreting pituitary adenoma, further expanding the clinical manifestations of pediatric pituitary tumors. Comprehensive pathological evaluation and close follow-up surveillance are crucial to the prompt delivery of the best therapeutic options in the context of this particularly aggressive pituitary tumor.

摘要

促甲状腺激素(TSH)分泌型垂体腺瘤在儿童期极为罕见,且在该年龄范围内尚未有此类肿瘤与其他垂体激素共同分泌的病例报道。我们报告一例小儿患者的单形态多激素垂体腺瘤,该肿瘤同时分泌TSH和生长激素(GH)。一名13岁男性患者出现身高增长速度加快(17.75厘米/年,高于正常均值9.55标准差)、体重减轻和视力损害。初步生化检查显示继发性甲状腺功能亢进。磁共振检查发现一个巨大的垂体肿瘤压迫周围结构,最初进行了经蝶窦手术。病理检查显示为非典型的、单形态多激素Pit-1谱系肿瘤,具有沉默亚型3腺瘤和嗜酸性干细胞腺瘤的混合特征。术后,继发性甲状腺功能亢进复发,GH和胰岛素样生长因子1(IGF1)水平均升高。此外,由于肿瘤复发,采取了包括手术、生长抑素类似物和放疗在内的多模式治疗方案。我们报告了首例小儿多激素分泌TSH和GH的垂体腺瘤病例,进一步扩展了小儿垂体肿瘤的临床表现。对于这种具有特别侵袭性的垂体肿瘤,全面的病理评估和密切的随访监测对于及时提供最佳治疗选择至关重要。

相似文献

1
Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.一名患有中枢性甲状腺功能亢进症的巨大青少年患者的 Pit-1 谱系单形性多激素垂体腺瘤。
Endocr Pathol. 2016 Mar;27(1):25-33. doi: 10.1007/s12022-015-9395-2.
2
Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.静默型 3 型垂体腺瘤并非总是静默的,它们代表分化不良的单型多激素分泌垂体瘤-1 谱系腺瘤。
Mod Pathol. 2016 Feb;29(2):131-42. doi: 10.1038/modpathol.2015.151. Epub 2016 Jan 8.
3
Hyperthyroidism caused by an ectopic thyrotropin-secreting tumor of the nasopharynx: a case report and review of the literature.鼻咽部异位分泌促甲状腺激素肿瘤所致甲状腺功能亢进症:1例报告并文献复习
Thyroid. 2013 Sep;23(9):1172-7. doi: 10.1089/thy.2012.0574. Epub 2013 Aug 27.
4
Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.促甲状腺激素分泌型垂体腺瘤的临床病理特征及治疗结果:一项90例的单中心研究
J Neurosurg. 2014 Dec;121(6):1462-73. doi: 10.3171/2014.7.JNS1471. Epub 2014 Sep 19.
5
Clinical and morphological features of undifferentiated monomorphous GH/TSH-secreting pituitary adenoma.未分化单形性生长激素/促甲状腺激素分泌型垂体腺瘤的临床及形态学特征
Eur J Endocrinol. 1999 Jun;140(6):528-37. doi: 10.1530/eje.0.1400528.
6
Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.Pit-1 阳性多激素分泌垂体大腺瘤伴中枢性甲亢:罕见病例报告及文献复习。
BMC Endocr Disord. 2022 Dec 21;22(1):325. doi: 10.1186/s12902-022-01220-2.
7
Thyrotropin secreting pituitary adenoma accompanying a silent somatotropinoma.促甲状腺激素分泌型垂体腺瘤伴无功能生长激素瘤
Turk Neurosurg. 2011;21(3):403-7. doi: 10.5137/1019-5149.JTN.2642-09.2.
8
Silent pituitary plurihormonal adenoma: clinical relevance of immunohistochemical analysis.沉默性垂体多激素腺瘤:免疫组化分析的临床意义
Rev Med Inst Mex Seguro Soc. 2019 Apr 1;57(1):48-55.
9
Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon.垂体 1 谱系和 SF-1 谱系的多激素垂体瘤,伴有同步碰撞促皮质激素瘤:一种可能的干细胞现象。
Endocr Pathol. 2019 Mar;30(1):74-80. doi: 10.1007/s12022-018-9562-3.
10
The TSH secretion in the human pituitary adenomas.人垂体腺瘤中的促甲状腺激素分泌。
Pathol Res Pract. 1988 Sep;183(5):596-600. doi: 10.1016/S0344-0338(88)80019-0.

引用本文的文献

1
A Brief Overview of Molecular Biology in Pituitary Adenomas with a Focus on Aggressive Lesions.垂体腺瘤分子生物学概述:聚焦侵袭性病变
Int J Mol Sci. 2025 Apr 15;26(8):3717. doi: 10.3390/ijms26083717.
2
Unusual Presentation of Craniopharyngioma Pituitary Mass in a 71-Year-Old Female: A Case Report.71岁女性颅咽管瘤垂体肿块的不寻常表现:一例报告
Case Rep Endocrinol. 2024 Oct 4;2024:1333552. doi: 10.1155/2024/1333552. eCollection 2024.
3
[Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients].

本文引用的文献

1
Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.静默型 3 型垂体腺瘤并非总是静默的,它们代表分化不良的单型多激素分泌垂体瘤-1 谱系腺瘤。
Mod Pathol. 2016 Feb;29(2):131-42. doi: 10.1038/modpathol.2015.151. Epub 2016 Jan 8.
2
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.内分泌疾病的管理:垂体肿瘤的临床病理分类和分子标志物,用于制定个体化治疗策略。
Eur J Endocrinol. 2014 Mar 13;170(4):R121-32. doi: 10.1530/EJE-13-1031. Print 2014 Apr.
3
[促甲状腺素分泌型垂体腺瘤:45例患者的临床特征及治疗结果]
Probl Endokrinol (Mosk). 2023 Sep 27;70(2):23-36. doi: 10.14341/probl13325.
4
Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2.无明显谱系分化的垂体肿瘤表达干细胞标志物 SOX2。
Pituitary. 2024 Jun;27(3):248-258. doi: 10.1007/s11102-024-01385-0. Epub 2024 Mar 14.
5
Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.儿童和青少年垂体腺瘤的诊断和管理共识指南:第 2 部分,特定疾病。
Nat Rev Endocrinol. 2024 May;20(5):290-309. doi: 10.1038/s41574-023-00949-7. Epub 2024 Feb 9.
6
Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma.多激素垂体腺瘤的发病机制、临床特征及治疗
Front Neurosci. 2024 Jan 8;17:1323883. doi: 10.3389/fnins.2023.1323883. eCollection 2023.
7
Clinical features and therapeutic outcomes of GH/TSH cosecreting pituitary adenomas: experience of a single pituitary center.GH/TSH 共分泌垂体腺瘤的临床特征和治疗结果:单中心经验。
Front Endocrinol (Lausanne). 2023 May 30;14:1197244. doi: 10.3389/fendo.2023.1197244. eCollection 2023.
8
Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.Pit-1 阳性多激素分泌垂体大腺瘤伴中枢性甲亢:罕见病例报告及文献复习。
BMC Endocr Disord. 2022 Dec 21;22(1):325. doi: 10.1186/s12902-022-01220-2.
9
Clinical and Therapeutic Characteristics of Pituitary TSH-Secreting Adenoma in Adolescent-Onset Patients: Six Case Studies and Literature Review.青少年起病的垂体促甲状腺素(TSH)分泌腺瘤的临床和治疗特点:六例病例研究及文献复习。
Front Endocrinol (Lausanne). 2021 Dec 23;12:771673. doi: 10.3389/fendo.2021.771673. eCollection 2021.
10
Central Hyperthyroidism due to Thyroid-Stimulating Hormone-Secreting Pituitary Microadenoma in an Adolescent Boy: Case Report and Review of the Literature.一名青春期男孩因分泌促甲状腺激素的垂体微腺瘤导致中枢性甲状腺功能亢进:病例报告及文献复习
Case Rep Endocrinol. 2021 Mar 20;2021:5573231. doi: 10.1155/2021/5573231. eCollection 2021.
Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.
家族性孤立性垂体腺瘤(FIPA)和由于芳香烃受体相互作用蛋白(AIP)基因突变引起的垂体腺瘤易感性。
Endocr Rev. 2013 Apr;34(2):239-77. doi: 10.1210/er.2012-1013. Epub 2013 Jan 31.
4
Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.13 岁女孩无症状促甲状腺激素分泌垂体大腺瘤:生长抑素类似物一线治疗成功。
Thyroid. 2012 Oct;22(10):1076-9. doi: 10.1089/thy.2012.0077. Epub 2012 Sep 4.
5
Biomarkers of aggressive pituitary adenomas.侵袭性垂体腺瘤的生物标志物。
J Mol Endocrinol. 2012 Aug 30;49(2):R69-78. doi: 10.1530/JME-12-0113. Print 2012 Oct.
6
Clinicopathological analysis of nonfunctioning pituitary adenomas in patients younger than 25 years of age.25岁以下无功能垂体腺瘤患者的临床病理分析
J Neurosurg Pediatr. 2012 May;9(5):511-6. doi: 10.3171/2012.1.PEDS11330.
7
Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.在一个 443 例患者的前瞻性单中心队列中,散发垂体腺瘤中的种系 AIP 突变:患病率。
J Clin Endocrinol Metab. 2012 Apr;97(4):E663-70. doi: 10.1210/jc.2011-2291. Epub 2012 Feb 8.
8
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: executive summary.美国临床内分泌医师协会肢端肥大症诊断与治疗临床实践医学指南——2011年更新:执行摘要
Endocr Pract. 2011 Jul-Aug;17(4):636-46. doi: 10.4158/ep.17.4.636.
9
Resistance to somatostatin analogs in acromegaly.肢端肥大症中生长抑素类似物的耐药性。
Endocr Rev. 2011 Apr;32(2):247-71. doi: 10.1210/er.2010-0002. Epub 2010 Dec 1.
10
Thyroid-stimulating hormone (thyrotropin)-secretion pituitary adenoma in an 8-year-old boy: case report.8 岁男孩促甲状腺激素(促甲状腺素)分泌垂体腺瘤:病例报告。
Pituitary. 2012 Mar;15(1):110-5. doi: 10.1007/s11102-010-0275-y.